Firma DAIICHI SANKYO EUROPE, Autor bei PR-Web

ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial

Posted on 29. May 2020 by Firma DAIICHI SANKYO EUROPE Posted in General Tagged anc, breast, btd, cancer, constipation, curea, enhertu, her2, ild, irinotecan, lvef, neutropenia, nsclc, pneumonitis, with

First HER2 directed therapy to show an improvement in overall survival for previously-treated metastatic gastric cancer with a 41% reduction in the risk of death versus chemotherapy Breakthrough Therapy Designation recently granted in the U.S. for ENHERTU in this setting […]

ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial

Posted on 29. May 2020 by Firma DAIICHI SANKYO EUROPE Posted in General Tagged anc, breast, btd, cancer, constipation, deruxtecan, egfr, enhertu, ild, irinotecan, lvef, nsclc, patients, pediatric, with

Results from the phase 2 DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful activity in patients with HER2 positive unresectable and/or metastatic colorectal cancer who received at least two prior lines […]

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial

Posted on 29. May 2020 by Firma DAIICHI SANKYO EUROPE Posted in General Tagged anc, breast, btd, cancer, constipation, corticosteroid, fever, ild, lvef, nsclc, orphan, patients, pediatric, PFS, with

9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Breakthrough Therapy Designation recently granted in the U.S. in this setting Results from the ongoing phase 2 DESTINY-Lung01 trial showed Daiichi Sankyo […]